Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (S<underline>EASI</underline>DE CHINA)

被引：0
|
作者：
Zhang, Jianzhong [1 ]
Silverberg, Jonathan, I [2 ]
Guo, Jiawang [3 ]
Yun, Jili [3 ]
Pan, Wuban [3 ]
Wei, Zheng [4 ]
Collazo, Raul [4 ]
机构：
[1] Peking Univ, Dept Dermatol, Peoples Hosp, Beijing, Peoples R China
[2] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA
[3] Suzhou Connect Biopharmaceut Ltd, Taicang, Peoples R China
[4] Connect Biopharm LLC, San Diego, CA USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷
关键词：
moderate-to-severe atopic dermatitis; rademikibart; CBP-201; therapy; IL-4R alpha;
D O I：
10.1093/bjd/ljae266.086
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
712
引用
收藏
页数：2
相关论文
共 32 条
  • [31] Maintenance of clinical effect in patients with moderate-to-severe Crohn's disease treated with filgotinib, a selective JAK1 inhibitor: exploratory 20-week data analysis of the phase 2 FITZROY study
    Vermeire, S.
    Schreiber, S.
    Petryka, R.
    Kuehbacher, T.
    Hebuterne, X.
    Roblin, X.
    Klopocka, M.
    Goldis, A.
    Wisniewska-Jarosinska, M.
    Baranovsky, A.
    Sike, R.
    Stoyanova, K.
    Meuleners, L.
    Tasset, C.
    Van der Aa, A.
    Harrison, P.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S13 - S14
  • [32] MAINTENANCE OF CLINICAL EFFECT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE TREATED WITH FILGOTINIB, A SELECTIVE JAK1 INHIBITOR: EXPLORATORY 20-WEEK DATA ANALYSIS OF THE PHASE 2 FITZROY STUDY
    Vermeire, Severine
    Schreiber, Stefan
    Petryka, Robert
    Kuehbacher, Tanja
    Hebuterne, Xavier
    Roblin, Xavier
    Klopocka, Maria
    Goldis, Adrian
    Wisniewska-Jarosinska, Maria A.
    Baranovsky, Andrei
    Sike, Robert
    Stoyanova, Kremena
    Meuleners, Luc
    Tasset, Chantal T.
    Van der Aa, Annegret
    Harrison, Pille
    GASTROENTEROLOGY, 2017, 152 (05) : S601 - S601
1234